

# The OMACS-PIL study - a randomised controlled study within the OMACS observational study

Lucy Culliford (✉ [Lucy.Culliford@bristol.ac.uk](mailto:Lucy.Culliford@bristol.ac.uk))

CTEU Bristol <https://orcid.org/0000-0002-9255-6617>

Rachel Brierley

CTEU Bristol, BTC

Maddie Clout

CTEU Bristol, BTC

Rebecca Evans

CTEU Bristol, BTC

Rachel Maishman

CTEU Bristol, BTC

Dawn Phillips

CTEU Bristol, BTC

Hana Tabusa

CTEU Bristol, BTC

Barney Reeves

CTEU Bristol, BTC

Chris A Rogers

CTEU Bristol, BTC

## Methodology

**Keywords:** Patient Information Leaflet, randomised, study within a study, recruitment, consent

**Posted Date:** May 2nd, 2019

**DOI:** <https://doi.org/10.21203/rs.2.9438/v1>

**License:**  This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

**Version of Record:** A version of this preprint was published on December 27th, 2019. See the published version at <https://doi.org/10.1186/s13063-019-3958-3>.

## Abstract

Background There has been little research to investigate whether the appearance of paper Patient Information Leaflets (PILs) used to describe research studies to potential participants influences their decision to take part. Embedding a Study Within a Study (SWAS) is an efficient way of answering this type of methodological question. We included a randomised SWAS within a large cohort study, Outcome monitoring After Cardiac Surgery (OMACS), to address this question. Methods Potential participants for the OMACS study were randomised to receive one of three PILs, identical in content but with varying formatting and use of colour: PIL A (enhanced format), PIL B (hybrid format) and PIL C (standard format). Consent to OMACS was the primary outcome. Consent rates using the three different PIL formats were collected and compared. Results For the SWAS, 1517 PILs were sent to potential participants and 640 (42%) consented to take part in OMACS. PIL B had the highest recruitment rate, with 45% of patients consenting to participation; 40% and 41% of patients consented to participation with PIL A and C respectively. Compared to PIL C, the consent rate was 4% higher with PIL B (45% versus 41%, 95% Confidence Interval (CI) -2% to +10%, p=0.16) and 1% lower with PIL A (40% versus 41%, 95% CI -7% to +5%, p=0.72). Conclusions PIL B, a hybrid format, led to the highest consent rate, and this format is being used for the remainder of the host study and will be used to inform the design of PILs for other research studies.

## Background

Much research has been conducted on how to improve Patient Information Leaflets (PILs), the consent process and recruitment in Randomised Controlled Trials (RCTs) and to improve response rates to postal questionnaires and this is summarised in several reviews [1-6]. The main focus of this research with respect to PILs has been on the readability or length of PILs [7-15], use of different media such as audio-visual materials [5], or interactive electronic materials [16] rather than how the appearance of paper PILs can be improved. The outcomes have been patients' understanding of the study, or satisfaction with the informed consent procedure. There has been less focus on whether recruitment rates can be improved, leading to a lack of evidence in this area. The conclusion of a Cochrane review [4] was that there is currently no clear evidence as to whether modifications to the information presented to participants improves recruitment to RCTs. This conclusion is consistent with that of previous reviews that reported that more research is required[1, 2].

With respect to the format of the PIL, Reinert and colleagues [11] performed a quantitative and qualitative analysis of study PILs and concluded that information presented to potential participants "*needs to be well structured and designed in an appealing manner*". This study focused on how the appearance of the paper PIL might affect the decision to take part in a study, rather than the content. However, efforts were still made to make sure the content was readable and the length of the PIL kept to a minimum. This research was conducted as a Study Within a Study (SWAS) by nesting it within a large cohort study, Outcome Monitoring After Cardiac Surgery (OMACS). The objective of the SWAS, OMACS-PIL, was to compare rates of consent using different formats of the host study PIL.

# **Methods**

## **The Main Study (OMACS)**

The OMACS study is an ongoing cohort study aiming to gain consent from cardiac surgery patients at our institution (University Hospitals Bristol NHS Foundation Trust) to collect and use quality of life data, plus routinely collected data on their operation and subsequent recovery to be used in a range of research studies. Patients are approached for consent by post 3 months after their operation. The inclusion criteria for OMACS are adult participants over the age of 18 years who have undergone cardiac surgery at our institution, and around 1000 patients per year are approached to take part. The only patients not eligible to participate are prisoners, patients without the mental capacity to give consent and patients whose main residence is outside the United Kingdom. OMACS is ongoing and the results of the SWAS will be applied to future recruitment to OMACS. This study was chosen as it uses postal consent, where the appearance of the PIL may have more impact than face-to-face consent, plus the large target population meant that the SWAS could be completed quickly.

## **The SWAS (OMACS-PIL)**

OMACS – PIL was an RCT to investigate whether recruitment to the main OMACS study was affected by the format of the information provided to the potential participant. Three different information leaflets were prepared, each with the same content but using different styles and formatting. PIL A (enhanced format) and PIL B (hybrid format) were produced with a specialised graphics package called InDesign (Adobe Systems Incorporated) and PIL C (standard format) was produced using Microsoft Word (Microsoft Corporation). PIL A was a full colour tri-fold leaflet, PIL B was a double-sided A4 sheet using columns to break the text up and some colour on headings, and PIL C was a black and white A4 double-sided sheet with “standard” formatting. Examples of each format can be seen in Figure 1. Potential participants were randomly assigned to receive either PIL A, B or C in the ratio of 1:1:1.

## **The Study Population**

The study population for OMACS-PIL comprised patients eligible for the OMACS study during the period of the SWAS. With the approval of an NHS REC (ref 14/EM/1222), patients were not informed of the SWAS as knowledge of the SWAS may have influenced how they viewed the PIL.

## **Outcome**

The outcome measure was consent to OMACS in each of the groups receiving PIL A, B or C.

## **Sample size**

Assuming a consent rate of 70% with PIL C (based on historic data from a similar system which ran over several years[17]), a sample size of 1590 (530 per group) would give 90% power to detect a 10% difference in consent rate between any pair of PIL formats, with an overall significance level of 5% (with a

Bonferroni correction for the three comparisons). This was the number of patients to be sent a PIL, rather than the number of patients required to consent.

## Statistical Analysis

The consent rates from the three different PIL formats were described and the differences in consent rate between pairs of PILs were calculated with 95% confidence intervals using Stata version 15.1 (StataCorp LP, College Station, Tex). Analysis took place at the end of the recruitment period for the SWAS.

## Public and patient involvement (PPI)

In order to get some qualitative information about the PILs, the PILs were presented to the Bristol Biomedical Research Unit Cardiovascular PPI group which is made up of representatives who have had cardiac surgery, to elicit their preferences for the format and appearance of the PILs and the reasons for their preferences.

## Results

For the duration of the SWAS, 1517 invitation letters and PILs were sent to eligible cardiac surgery patients. The numbers of each format of PIL sent were: Format A 505, Format B 506 and Format C 506.

The age and sex of the target population is described in Table 1. The mean age was 64.9 years (standard deviation 13.4), and 1079/1517, 71.1% were male. The average age and proportion of male patients was very similar across the 3 groups (see Table 1).

In total, 640 patients (42%) consented to take part in OMACS. Consent rates across the three PIL formats are shown in Fig 2. PIL B had the highest recruitment rate, with 45% of patients consenting to participation and PIL A had the lowest recruitment rate, with 40% of patients consenting to participation. Compared to PIL C ('standard' format) the consent rate was 4% higher with PIL B (95% confidence interval (CI) -2% to +10%, p=0.16) and 1% lower with PIL A (95% CI -7% to +5%, p=0.72).

When the different PIL formats were presented to our Bristol Biomedical Research Unit Cardiovascular PPI group, their general preference was for PIL B, and their least favourite was PIL A. The PPI group felt very strongly that PIL A (Enhanced format) looked too professional, and looked like advertising material, similar to leaflets that are posted through letterboxes 'advertising takeaways'. They also did not like the fact that the study logo took up most of the front page of PIL A, when on receipt of the PIL they would not know what OMACS was. By contrast, with PIL B and PIL C, they could quickly understand that OMACS was a research study. Although the group did not dislike PIL C (standard), on balance they felt that the columnar presentation of PIL B made it more 'attractive' and easier to read.

## Discussion

OMACS-PIL has provided some evidence that the formatting of a PIL can influence the perception of the study by potential participants, although the differences in consent rates were not statistically significant. The research team had hypothesised that PIL A would be most popular, as it looked the 'most professional', but it was exactly this aspect that the PPI group did not like. The consistency between the quantitative finding and the PPI feedback reinforces the benefit of PPI being an integral part of research.

The sample size achieved was just short of the 1590 target. This is because, due to the lower than expected rates of consent across all PILs, the timing and mode of consent was changed to seeking face-to-face consent at the time of the admission for the cardiac operation. The decision to change to face-to-face consent coincided with the sample size for the SWAS almost being met, and the decision was made to halt OMACS-PIL at this point.

The modest increase in recruitment with PIL B is consistent with other research on the design of consent materials, however much of this previous research has included other interventions alongside changes to the PIL. For instance, in a RCT within the Avon Longitudinal Study of Parents and Children Study, potential participants were randomised to receive one of eight combinations of three interventions: a prior-notification postcard or no contact, a standard or professionally designed consent pack, and a phone or postal reminder[18]. Of these interventions, the most effective was the reminder phone call with a 6.4% higher response rate (95% CI +2.3 to +10.6%; P = 0.002). The professionally designed consent pack had some impact, increasing response rates by 2.7% (95% CI: -0.06% to 5.5%; P = 0.06), but the prior notification postcard had no effect. Phone call reminders can have significant resource implications, hence our decision not to include this as an intervention.

The MRC START programme has also looked at the format of the paper PIL, but this was part of an 'enhanced' PIL where the wording was refined after several rounds of user testing [12, 13]. This approach has resource implications and of the work published so far there have been only marginal improvements in recruitment [12, 15]. The Healthlines studies showed modest increases in a positive response to an invitation to participate in the study when using the enhanced PIL that, like OMACS-PIL, were not statistically significant (19% versus 16%, difference of 2.9%, 95% CI = -1.1% to 6.9% in the Healthlines Depression study, n = 1364, and 24.0% versus 21.9%, difference of 2.0%, 95% CI -4.3% to 8.4% in the Healthlines CVD study, n = 671) [12]. In Early CDT Lung Cancer Scotland (ECLS), the proportion of patients who positively responded to the invitation was 224/1136 (19.7%) in the intervention group (optimised PIL) and 205/1126 (18.2%) in the control group (difference of 1.5%, 95% CI = -1.7% to 4.7%) [15]. In addition to these MRC Start studies, the REFORM study concluded that there was limited evidence as to the benefit of using optimised information materials on recruitment and retention rates [14] and the recently updated Cochrane review of methods to enhance recruitment to RCTs, concluded that 'Using a tailored, user-testing approach to develop participant information leaflets makes little or no difference to recruitment.'[19]. There has been a Cochrane review of methods to increase response rates to postal questionnaires [6] but this focused on the design of the questionnaire or the method of postage (e.g. first class post) and not on the PIL provided to participants.

Resource implications for developing electronic media and the limited existing evidence that it can improve recruitment [5] were the reasons a multi-media approach was not explored in OMACS-PIL.

One area for concern in OMACS is that the overall response rate was much lower than expected. The expected response rate was based on similar work involving postal consent of cardiac surgery patients (Long Term Monitoring, LTM), which had been as high as 80% [17]. There are a few differences between the studies: the timing of approach for consent was at 3 months versus 12 months after cardiac surgery, and the ‘packs’ sent to OMACS patients had more documents and offered more choices in how to participate. LTM was conducted purely by post, whereas OMACS allowed participants to register, consent and complete questionnaires online if they preferred. This extra complexity may have contributed to the lower consent rate. The options were offered to allow participants to complete the study in the way most convenient to them, but it may be that the extra ‘thinking’ involved meant that they did not take part at all. Again, this shows that researchers need to not assume they know what patients want.

A limitation of this study is that all 3 PIL formats would not necessarily be suitable for all studies. The information required to convey this study was limited as OMACS is an observational study and not an RCT, and therefore was easily incorporated into the different formats. The format of PIL A may not be suitable for interventional trials where more information needs to be included. Even in OMACS, the volume of information included in the PIL has increased since the SWAS was conducted due to the requirements of NHS Digital, to obtain Hospital Episode Statistics which is a feature of the main study. The extra information was easily incorporated into PILs B and C but would have been more challenging to incorporate into PIL A due to the way that the information was presented and formatted. To make PIL B easier to use in OMACS and other studies without the need for specialist software, we have now recreated the format in Microsoft Word (Microsoft Corporation), and this format is now being used for the host study.

The PPI work included was informal and the PPI group was relatively small. However, their opinions were consistent with the quantitative finding of the SWAS.

A strength of OMACS-PIL is that the intervention could be implemented in any study and does not require rounds of user acceptability testing to see a positive improvement in recruitment rates as required by other projects (e.g. MRC START) or extra resources as required with telephone contact or using a multimedia approach. This means that it can be implemented with minimal or no impact on the study budget. OMACS-PIL was also randomised, and the participants were unaware of the SWAS and so were effectively ‘blinded’ to the interventions. However, based on the results of OMACS-PIL and the other similar studies, any improvement in consent rates are likely to be small.

## Conclusions

The ‘hybrid’ PIL (PIL B) was preferred by the PPI group and resulted in a slightly higher consent rate to the host study than PIL A (enhanced format) or PIL C (standard format). PIL A, which was the most expensive to produce, was the least preferred option for the PPI group and did not improve consent rates.

PIL B is now being used as the PIL for the remainder of the OMACS study, and the findings from this study are being used to inform the design of PILs for interventional trials.

## Abbreviations

HES Hospital episode statistics

LTM Long term monitoring

OMACS Outcome monitoring after cardiac surgery

PIL Patient information leaflet

PPI Public and patient involvement

RCT Randomised controlled trial

REC Research ethics committee

SWAS Study within a study

## Declarations

### Ethics approval and consent to participate

The study was approved by NRES Committee East Midlands - Nottingham 2 (14/EM/1222).

### Consent for publication

Not applicable.

### Availability of data and material

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

### Competing interests

The authors declare that they have no competing interests.

### Funding

This study was supported by the NIHR Biomedical Research Centre at University Hospitals Bristol NHS Foundation Trust and the University of Bristol. The views expressed in this publication are those of the author(s) and not necessarily those of the NHS, the National Institute for Health Research or the Department of Health.

Support was also obtained from the British Heart Foundation Personal Chair held by Gianni Angelini (CH/1992027/7163).

### Authors' contributions

LC designed the study with RB, RM and CR, and drafted the manuscript; JL created the enhanced and hybrid PILs; RE conducted the statistical analyses; DP, HT and MC reviewed and contributed to the writing of the manuscript. All authors read and approved the final manuscript

### Acknowledgements

Susan Plummer and Frances Gill sent out the PILs and collated the responses. Jenny Lamb designed PIL A and B.

## References

1. Watson, J.M. and D.J. Torgerson, *Increasing recruitment to randomised trials: a review of randomised controlled trials*. BMC Med Res Methodol, 2006. **6**: p. 34.
2. Caldwell, P.H., et al., *Strategies for increasing recruitment to randomised controlled trials: systematic review*. PLoS Med, 2010. **7**(11): p. e1000368.
3. Nishimura, A., et al., *Improving understanding in the research informed consent process: a systematic review of 54 interventions tested in randomized control trials*. BMC Med Ethics, 2013. **14**: p. 28.
4. Treweek, S., et al., *Methods to improve recruitment to randomised controlled trials: Cochrane systematic review and meta-analysis*. BMJ Open, 2013. **3**(2).
5. Synnot, A., et al., *Audio-visual presentation of information for informed consent for participation in clinical trials*. Cochrane Database Syst Rev, 2014. **5**: p. CD003717.
6. Edwards, P., et al., *Methods to increase response rates to postal questionnaires*. Cochrane Database Syst Rev, 2007(2): p. MR000008.
7. Davis, T.C., et al., *Informed consent for clinical trials: a comparative study of standard versus simplified forms*. J Natl Cancer Inst, 1998. **90**(9): p. 668-74.
8. Brierley, G., R. Richardson, and D.J. Torgerson, *Using short information leaflets as recruitment tools did not improve recruitment: a randomized controlled trial*. J Clin Epidemiol, 2012. **65**(2): p. 147-54.
9. Coyne, C.A., et al., *Randomized, controlled trial of an easy-to-read informed consent statement for clinical trial participation: a study of the Eastern Cooperative Oncology Group*. J Clin Oncol, 2003. **21**(5): p. 836-42.
10. Bjorn, E., P. Rossel, and S. Holm, *Can the written information to research subjects be improved?—an empirical study*. J Med Ethics, 1999. **25**(3): p. 263-7.
11. Reinert, C., et al., *Quantitative and qualitative analysis of study-related patient information sheets in randomised neuro-oncology phase III-trials*. Eur J Cancer, 2014. **50**(1): p. 150-8.

12. Man, M.S., et al., *Improving recruitment to a study of telehealth management for long-term conditions in primary care: two embedded, randomised controlled trials of optimised patient information materials*. Trials, 2015. **16**: p. 309.
13. *MRC Start*. [cited 2018 27/02/2018]; Available from:  
<http://research.bmh.manchester.ac.uk/mrcstart/about/>
14. Cockayne, S., et al., *An optimised patient information sheet did not significantly increase recruitment or retention in a falls prevention study: an embedded randomised recruitment trial*. Trials, 2017. **18**(1): p. 144.
15. Parker, A., et al., *The effect of optimised patient information materials on recruitment in a lung cancer screening trial: an embedded randomised recruitment trial*. Trials, 2018. **19**(1): p. 503.
16. Kirkby, H.M., et al., *Informing potential participants about research: observational study with an embedded randomized controlled trial*. PLoS One, 2013. **8**(10): p. e76435.
17. Rogers, C.A., et al., *Coronary surgery in patients with preexisting chronic atrial fibrillation: early and midterm clinical outcome*. Ann Thorac Surg, 2006. **81**(5): p. 1676-82.
18. Boyd, A., et al., *Professionally designed information materials and telephone reminders improved consent response rates: evidence from an RCT nested within a cohort study*. J Clin Epidemiol, 2015. **68**(8): p. 877-87.
19. Treweek, S., et al., *Strategies to improve recruitment to randomised trials*. Cochrane Database Syst Rev, 2018. **2**: p. MR000013.

## Tables

**Table 1 - Patient demography, by PIL type**

		PIL A (n=505)	PIL B (n=506)	PIL C (n=506)	Overall (n=1517)
Age (years)	Mean (SD)	64.6 (13.5)	64.7 (14.2)	65.4 (12.5)	64.9 (13.4)
Sex (male)	n (%)	356/505 (70.5%)	368/506 (72.7%)	355/506 (70.2%)	1079/1517 (71.1%)

## Figures

**A**

This will be clearly NHS staff or by researchers who would be the main role of confidentiality in NHS staff. The confidentiality of your medical records will be respected if at any time, you do not wish to be involved in any way in any report about the study.

**Further information and contact details**

If you have any concerns or questions about this study please contact us on 0117 342 1140. Please ask any questions before deciding whether or not to take part, or at any time during the study. For more information about our research, contact us on [www.BristolHeartOMACSSite.com](http://www.BristolHeartOMACSSite.com) or [www.NIHR.ac.uk](http://www.NIHR.ac.uk). All researchers in the NHS is looked after by an independent group of people called a Research Ethics Committee, to protect your interests. This study has been reviewed and given favourable opinion by NRES Committee Nottingham 2 REC.

OMACS Participant Information Leaflet A  
v02 03/10/09 4

**Participant Information Leaflet**  
**Outcome Monitoring After Cardiac Surgery**

**Local Principal Investigator:**  
**<insert PI contact details>**

**OMACS**

Thank you for reading this leaflet and considering taking part in our research.

**What is the purpose of the study?**

We would like to invite you, as taking part in our research study before you decide we would like you to understand why the research is being done and what it would involve for you. **Taking part in this research is voluntary.**

**Why have I been asked?**

We would like to invite you to take part in our research study before you decide we would like you to understand why the research is being done and what it would involve for you. **Taking part in this research is voluntary.**

**What will happen if I take part?**

We are inviting you to join the study because you recently had heart surgery at the Bristol Heart Institute (BHI). We are inviting all patients who recently had heart surgery here to take part.

**Do I have to take part?**

It is up to you to decide whether or not to take part in the research. Any decision you make will not affect the medical care you receive. If you decide not to take part you do not need to give a reason. If you decide to take part, you can withdraw at any time without giving a reason. If you choose to withdraw we will only use the data collected up to your withdrawal.

**What is the purpose of the study?**

The aim of this research (funded by the NHS) is to collect information about the medium- and long-term health of patients who have had heart surgery. We will use this information to help us to design future research studies. You can still take part in OMACS if you do not want your data to be used for other studies.

**Will my taking part in this study be kept confidential?**

All information collected about you during the course of this research will be kept strictly confidential. We will store information about you in a secure database at the coordinating site in Bristol, which will only be accessed by the research team. Occasionally we may need to check information in your medical records. This will be done by NHS staff or by researchers who would be the main role of confidentiality in NHS staff.

**Thank you for reading this leaflet and considering taking part in our research.**

**Local Principal Investigator:**  
**<insert PI contact details>**

**OMACS Participant Information Leaflet A v2.0 (2/11/2014)**

**B**

**<insert logos or header>**

**Participant Information Leaflet**  
**Outcome Monitoring After Cardiac Surgery**

**What is the purpose of the study?**

Social Care Information Centre (SQC), which collects information from all hospitals on behalf of the Government. All of this information is routinely collected by the NHS during your hospital treatment. To obtain information from the BHI, we will need to share your NHS medical records and date of birth with them. Any information about you will be kept strictly confidential by the researchers who will only be able to access your data if they are involved in ongoing studies.

**Further information and contact details**

If you have any concerns or questions about this study please contact us on 0117 342 1140. Please ask any questions before deciding whether or not to take part, or at any time during the study. For independent advice or to make a complaint you can contact Patient Safety & Complaints Team, Bristol Hospitals, University, Harbourside Street, Bristol, BS1 3NT. Tel 0117 342 1101. All research in the NHS is looked after by an independent group of people called a Research Ethics Committee, to protect your interests. This study has been reviewed and given favourable opinion by NRES Committee Nottingham 2 REC.

**Why have I been asked?**

We are inviting you to join the study because you recently had heart surgery at the Bristol Heart Institute (BHI). We are inviting all patients who recently had heart surgery here to take part.

**What will happen if I take part?**

You will be asked to complete a consent form and 2 short questionnaires, the first when you consent and another 9 months later. You can choose whether to complete these documents on paper or online (please see enclosed flowchart). Participants will receive an annual newsletter with news of our latest research.

**Taking part in the OMACS study does not involve hospital visits while the questionnaires are done at home at a time convenient to you.**

We will obtain information about you for the research from the BHI and the Health and Social Care Information Centre (NSCIC), which collects information from all hospitals on behalf of the Government. All of this information is routinely collected by the NHS during your hospital treatment. To obtain information from the NSCIC we will share your NHS medical records and date of birth with them. Any information about you will be kept strictly confidential by the researchers who will only be able to access your data if they are involved in other approved studies. We may also want to contact you again in future for other research studies. You can still take part in OMACS if you do not want your data to be used for other studies.

**Thank you for reading this leaflet and considering taking part in our research.**

**Local Principal Investigator:**  
**<insert PI contact details>**

**OMACS Participant Information Leaflet B v2.0 (2/11/2014)**

**C**

**<insert logos or header>**

**Participant Information Leaflet**  
**Outcome Monitoring After Cardiac Surgery**

**What is the purpose of the study?**

The aim of this research (funded by the NHS) is to collect information about the medium- and long-term health of patients who have had heart surgery. We will use this information to help us to design future research and to help to answer research questions in ongoing studies.

**Why have I been asked?**

We would like to invite you to take part in our research study. Before you decide we would like you to understand why the research is being done and what it would involve for you. **Taking part in this research is voluntary.**

**Why have I been asked?**

We are inviting you to join the study because you recently had heart surgery at the Bristol Heart Institute (BHI). We are inviting all patients who recently had heart surgery here to take part.

**Do I have to take part?**

It is up to you to decide whether or not to take part in this research. Any decision you make will not affect the medical care you receive. If you decide not to take part, you do not need to give a reason. If you decide to withdraw we will only use the data collected up to your withdrawal.

**What is the purpose of the study?**

The aim of the research (funded by the NHS) is to obtain information about the medium- and long-term health of patients who have had heart surgery. We will use this information to help us to design future research and to help to answer research questions in ongoing studies.

**What will happen if I take part?**

You will be sent a consent form and 2 short questionnaires, the first when you consent and another 9 months later. You can choose whether to complete these documents online or on paper (please see enclosed flowchart). Participants will receive an annual newsletter with news of our latest research.

**Taking part in the OMACS study does not involve hospital visits while the questionnaires are done at home at a time convenient to you.**

We will obtain information about you for the research from the BHI and the Health and Social Care Information Centre (NSCIC), which collects information from all hospitals on behalf of the Government. All of this information is routinely collected by the NHS during your hospital treatment. To obtain information from the NSCIC we will share your NHS medical records and date of birth with them. Any information about you will be kept strictly confidential by the researchers who will only be able to access your data if they are involved in other approved studies. We may also want to contact you again in future for other research studies. You can still take part in OMACS if you do not want your data to be used for other studies.


**Thank you for reading this leaflet and considering taking part in our research.**

**Local Principal Investigator:**  
**<insert PI contact details>**

**OMACS Study Participant Information Leaflet C v2.0**  
12 November 2014

**Figure 1**

Appearance of the PILs PIL A - tri-fold coloured leaflet produced using a graphic design package, InDesign, professional printers (= ENHANCED PIL); PIL B - coloured A4 sheet produced using a graphic design package, InDesign, professional printers (= HYBRID PIL); PIL C - black and white A4 sheet produced in Microsoft Word (= STANDARD PIL)



**Figure 2**

Consent rates by PIL type